loading page

Drug utilization study in patients with SARS-CoV-2 in an intensive care unit
  • +3
  • Miguel Sevilla Mendez,
  • Ana María Téllez López,
  • Giovanni Gómez Barragán,
  • Ivette Reyes Hernández,
  • Claudia Velázquez González,
  • Isis Beatriz Bermudez Camps
Miguel Sevilla Mendez
Hospital H+ Querétaro
Author Profile
Ana María Téllez López
Universidad Autonoma del Estado de Hidalgo ICSa
Author Profile
Giovanni Gómez Barragán
Hospital Infantil de México Federico Gómez
Author Profile
Ivette Reyes Hernández
Universidad Autonoma del Estado de Hidalgo ICSa
Author Profile
Claudia Velázquez González
Universidad Autonoma del Estado de Hidalgo ICSa
Author Profile
Isis Beatriz Bermudez Camps
Universidad Autonoma del Estado de Hidalgo ICSa
Author Profile

Abstract

Aim: To evaluate the treatments used in patients diagnosed with SARS-CoV-2 infection hospitalized in critical care service, through a prescription indication study. Methods: A longitudinal observational study of medication use, of the indication-prescription type with elements of the therapeutic scheme and practical consequences, was carried out. The sample was characterized from the sociodemographic, clinical, and pharmacotherapeutic points of view. The prescription was evaluated through the indicators: indication, therapeutic scheme, treatment individualization, and drug combinations. The detected adverse reactions were classified according to their causality by the Naranjo Algorithm, their severity, their clinical significance, and according to their mechanism by Rawlins and Thompson. Results: In the sample (N=77), the male gender predominated (79%) between 27-59 years old (64%), alcohol consumer (62%), hypertensive (33%) with long hospital stay (51%). 417 medications were analyzed, being antibiotics (50.6%) being the most prescribed. 73.4% of the therapeutic schemes were correct, however, 26.6% had problems with the therapeutic schemes due to the use of incorrect doses, intervals, and duration of treatment, as well as risky interactions. Two probable adverse reactions were detected, mild, non-serious, and type A and B according to Rawlins and Thompson. Conclusions: The results obtained will allow the pharmaceutical professional to create risk matrices that guarantee a timely intervention in the health team to contribute to the rational and safe use of medicines in patients infected with SARS-CoV-2.